Correction: Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes

Oncotarget. 2018 Jul 20;9(56):30936. doi: 10.18632/oncotarget.25856.

M Teresa Cedena^#^{1

2}, Inmaculada Rapado^#^{1

2}, Alejandro Santos-Lozano^{2

3}, Rosa Ayala^{1

2}, Esther Onecha^{1

2}, María Abaigar⁴, Esperanza Such⁵, Fernando Ramos⁶, José Cervera^{5

7}, María Díez-Campelo^{4

8}, Guillermo Sanz⁵, Jesús Hernández Rivas^{4

8}, Alejandro Lucía^{2

9}, Joaquin Martínez-López^{1

2}

¹ Hematology Department, Hospital Universitario 12 Octubre, CNIO, Universidad Complutense, Madrid, Spain.
² Research Institute of Hospital 12 de Octubre ('i+12'), Madrid, Spain.
³ GIDFYS, European University Miguel de Cervantes, Valladolid, Spain.
⁴ IBSAL, Cancer Research Center (USAL-CSIC), Salamanca, Spain.
⁵ Hematology Department, Hospital Universitario La Fe, Valencia, Spain.
⁶ Hematology Department, Hospital Universitario de León, and IBIOMED, Universidad León, León, Spain.
⁷ Genetics Unit, Hospital Universitario La Fe, Valencia, Spain.
⁸ Hematology Department, Hospital Universitario de Salamanca, Salamanca, Spain.
⁹ Universidad Europea de Madrid, Madrid, Spain.

^# Contributed equally.

Abstract

[This corrects the article DOI: 10.18632/oncotarget.22157.].